Predicted protein targets (top 6)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HTR2C | P28335 | 1/20 | 0.31 |
| ▸ | GRM1 | Q13255 | 2/20 | 0.30 |
| ▸ | TP53 | P04637 | 1/20 | 0.30 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.30 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.30 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL11926941 | 0.77 | ACHE (0.33) | GRM1TP53CYP3A4MAPK1SMN1; SMN2 | |
| SCHEMBL16171215 | 0.75 | GRM1 (0.32) | GRM1TP53CYP3A4MAPK1SMN1; SMN2 | |
| SCHEMBL20710542 | 0.73 | PTGS1 (0.31) | — | |
| SCHEMBL17248119 | 0.72 | OGA (0.41) | HTR2CGRM1TP53CYP3A4MAPK1 | |
| SCHEMBL15070829 | 0.71 | SYK (0.36) | GRM1TP53CYP3A4MAPK1SMN1; SMN2 | |
| SCHEMBL19131876 | 0.71 | CTNNB1 (0.35) | HTR2C | |
| SCHEMBL24803725 | 0.71 | HTR2C (0.43) | HTR2C | |
| SCHEMBL18237839 | 0.71 | HTR2C (0.43) | HTR2CSMN1; SMN2 | |
| SCHEMBL25803302 | 0.70 | NOS3 (0.33) | — | |
| SCHEMBL25060986 | 0.69 | HTR2C (0.42) | HTR2CSMN1; SMN2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20130165483-A1 | HETEROARYLS AND USES THEREOF | MILLENNIUM PHARMACEUTICALS, INC. (US) | 2013-06-27 | — | — | US | disclosed |
| US-20130165464-A1 | HETEROARYLS AND USES THEREOF | MILLENNIUM PHARMACEUTICALS, INC. (US) | 2013-06-27 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20130165483-A1 | HETEROARYLS AND USES THEREOF | PIK3R5, PIK3R4, PIK3C2B | HTR2C 1985/4885GRM1 1837/4885TP53 3057/4885 |
| US-20130165464-A1 | HETEROARYLS AND USES THEREOF | PIK3C2B, PI4KB, PIK3R4 | HTR2C 820/4885GRM1 1791/4885TP53 2932/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.